Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: AstraZeneca | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: AstraZeneca

Loss of exclusivity for Crestor and Seroquel XR in U.S. impacts earnings for the year

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

AstraZeneca
4Q Revenues: $5.8 billion (+3%)
4Q Earnings: $1.3 billion (-31%)
FY Revenues: $22.5 billion (-2%)
FY Earnings: $2.9 billion (-16%)
Comments: For the year, Product Sales were down 5% to $20.2 billion. Crestor sales declined 30% to $2.4 billion and Seroquel XR sales declined 55% to $332 million due to loss of exclusivity in the U.S. Brilinta and Farxiga sales were $1.1 billion for the year, up 29%. Symbicort sales were down 6% to $2.8 billion. Pulmicort sales were up 11% to $1.2 billion. Nexium sales were $2.0 billion, down 4%. Emerging Markets sales were up 6% with growth across all three main therapy areas and launches of new medicines. For the year, U.S. sales were down 16% to $6.2 billion impacted by Crestor and Seroquel XR losses of exclusivity, and adverse sales performance of Symbicort, down 12% to $1.1 billion. U.S. sales were up 9% to $1.8 billion in the quarter as a result of true-up adjustments in the U.S. relating to the first nine months of 2017. Product Sales in Europe were down 6% to $4.8 billion, partly driven by pricing pressures on Symbicort and the initial impact from generic competition to Crestor.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters